MarketCap
Facebook
X
Telegram
Neuronetics Total Non Current Liabilities | STIM
Annual Total Non Current Liabilities Neuronetics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 84.8 M | 77.8 M | 61.8 M | 26.6 M | 40.3 M | 39.5 M | 24.6 M | 32.4 M | 220 M | 189 M | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 220 M | 24.6 M | 79.6 M |
Quarterly Total Non Current Liabilities Neuronetics
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 82.7 M | 81.6 M | 80.1 M | 84.8 M | 85.2 M | 75.3 M | 77.6 M | 77.8 M | 47.8 M | 48.2 M | 61.7 M | 61.8 M | 39.7 M | 39.9 M | 40.1 M | 26.6 M | 31.1 M | 35.6 M | 40.2 M | 40.3 M | 4.18 M | 39.4 M | 39.4 M | 39.5 M | 5.08 M | 5.21 M | 39.6 M | 24.6 M | 29.1 M | 33 M | 36.2 M | 32.4 M | 27.3 M | 31.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 85.2 M | 4.18 M | 45.4 M |
Total Non Current Liabilities of other stocks in the Diagnostics research industry
| Issuer | Total Non Current Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Global Cord Blood Corporation
CO
|
2.53 B | - | - | $ 399 M |  China |
 |
Genetic Technologies Limited
GENE
|
161 K | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
37.1 M | - | 0.12 % | $ 80.1 M | China |
 |
Aspira Women's Health
AWH
|
3.49 M | - | -6.19 % | $ 10.5 M |  USA |
 |
Check-Cap Ltd.
CHEK
|
16 K | - | - | $ 9.42 M |  Israel |
 |
Exact Sciences Corporation
EXAS
|
981 M | - | - | $ 19.8 B | USA |
 |
National Research Corporation
NRC
|
84.3 M | $ 25.62 | 0.55 % | $ 573 M | USA |
 |
Twist Bioscience Corporation
TWST
|
4.56 M | $ 120.83 | 0.18 % | $ 7.23 B | USA |
 |
Organovo Holdings
ONVO
|
588 K | - | -2.3 % | $ 19.4 M | USA |
 |
OpGen
OPGN
|
21.2 M | - | -16.95 % | $ 1.54 M | USA |
 |
PerkinElmer
PKI
|
2.96 B | - | -0.91 % | $ 14.7 B | USA |
 |
Soleno Therapeutics
SLNO
|
52.4 M | - | - | $ 2.69 B | USA |
 |
Enzo Biochem
ENZ
|
4.6 M | - | -8.98 % | $ 14.8 K | USA |
 |
Quest Diagnostics Incorporated
DGX
|
5.17 B | $ 257.93 | 1.18 % | $ 28.6 B | USA |
 |
Danaher Corporation
DHR
|
26.9 B | $ 230.45 | 1.76 % | $ 164 B | USA |
 |
IDEXX Laboratories
IDXX
|
597 M | $ 676.3 | 0.83 % | $ 54.4 B | USA |
 |
Illumina
ILMN
|
2.04 B | $ 213.05 | 2.43 % | $ 33 B | USA |
 |
Lantheus Holdings
LNTH
|
804 M | $ 100.61 | -0.09 % | $ 6.79 B | USA |
 |
Accelerate Diagnostics
AXDX
|
134 M | - | -61.36 % | $ 2.46 M | USA |
 |
Medpace Holdings
MEDP
|
73.8 M | $ 653.24 | 2.88 % | $ 18.8 B | USA |
 |
Mettler-Toledo International
MTD
|
1.61 B | $ 1 722.36 | 2.64 % | $ 35.5 B |  Schweiz |
 |
Natera
NTRA
|
245 M | $ 319.38 | -12.2 % | $ 43.7 B | USA |
 |
Charles River Laboratories International
CRL
|
2.8 B | $ 338.13 | 8.07 % | $ 16.8 B | USA |
 |
Koninklijke Philips N.V.
PHG
|
8.45 B | $ 30.33 | -0.57 % | $ 28.8 B |  Niderland |
 |
QIAGEN N.V.
QGEN
|
1.99 B | $ 50.36 | -0.98 % | $ 10.9 B | Niderland |
 |
RadNet
RDNT
|
1.09 B | $ 75.83 | -2.79 % | $ 5.7 B | USA |
 |
Senseonics Holdings
SENS
|
163 M | $ 8.58 | 7.38 % | $ 358 M | USA |
 |
T2 Biosystems
TTOO
|
60.6 M | - | -39.35 % | $ 313 K | USA |
 |
Biocept
BIOC
|
11.3 M | - | -13.05 % | $ 7.29 M | USA |
 |
Thermo Fisher Scientific
TMO
|
22.5 B | $ 694.85 | 2.62 % | $ 262 B | USA |
 |
Akumin
AKU
|
527 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Trinity Biotech plc
TRIB
|
106 M | $ 6.07 | 2.97 % | $ 2.18 B |  Irlanda |
 |
Brainsway Ltd.
BWAY
|
16.7 M | $ 11.12 | 4.81 % | $ 378 M | Israel |
 |
VolitionRx Limited
VNRX
|
3.45 M | $ 0.2 | 3.39 % | $ 25.2 M |  Singapore |
 |
Waters Corporation
WAT
|
1.28 B | $ 458.04 | 1.06 % | $ 27.3 B | USA |
 |
Exagen
XGN
|
27.8 M | $ 5.79 | -23.82 % | $ 125 M | USA |
 |
Guardant Health
GH
|
1.81 B | $ 151.28 | -1.4 % | $ 19 B | USA |
 |
Laboratory Corporation of America Holdings
LH
|
6.93 B | $ 366.98 | 1.02 % | $ 30.5 B | USA |
 |
IQVIA Holdings
IQV
|
15 B | $ 271.72 | 2.59 % | $ 46.7 B | USA |
 |
Quotient Limited
QTNT
|
201 M | - | -11.32 % | $ 1.1 M | Schweiz |
 |
Chembio Diagnostics
CEMI
|
24.8 M | - | 0.22 % | $ 16.8 M | USA |
 |
DermTech
DMTK
|
865 K | - | -11.32 % | $ 2.94 M | USA |
 |
Surmodics
SRDX
|
17.1 M | - | - | $ 608 M | USA |
 |
Invitae Corporation
NVTA
|
320 M | - | - | $ 21.2 M | USA |
 |
Syneos Health
SYNH
|
2.97 B | - | - | $ 4.46 B | USA |
 |
Motus GI Holdings
MOTS
|
2.16 M | - | -34.28 % | $ 263 K | Israel |
 |
Heska Corporation
HSKA
|
57.9 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
4.1 M | - | -20.0 % | $ 1.06 M | USA |